RxDoctor Payments DataLook up a doctor →

Yoel Vivas, MD

Clinical Cardiac Electrophysiology · Delray Beach, FLNPI 1619130291

Payments from drug & device makers

$307,837in general payments, 2019–2025

Across 1,546 payments — averaging $199.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$164K
  • Boston Scientific$57K
  • Elutia, Inc.$24K
  • Acutus Medical, Inc.$14K
  • Medtronic$12K
  • Biotronik Inc.$10K
  • plus $27K from 31 others
$66,900in research payments, 2019–2025

Across 11 payments — averaging $6081.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$67K

What the payments were for

  • Consulting fees$96,18336%
  • Speaking & faculty fees$85,20132%
  • Travel & lodging$34,88013%
  • Food & beverage$51,41819%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$307,837 in reported general payments places this provider in the 85th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$699,187
Medicare patients
1,565
Services billed
6,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$343,403
MultaqDronedarone Hcl88$95,170
XareltoRivaroxaban80$86,119
Dabigatran EtexilateDabigatran Etexilate Mesylate17$4,284
Metoprolol Succinate275$3,511
SotalolSotalol Hcl116$2,274
Amiodarone Hcl127$1,723
Flecainide Acetate56$1,668
Fludrocortisone Acetate26$811
ClopidogrelClopidogrel Bisulfate63$661
Digoxin27$607
Carvedilol71$507
Sucralfate54$482
Midodrine Hcl16$449
Pantoprazole Sodium62$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$486$343,403385 claims
Sanofi-aventis U.S. LLCMultaq$352$95,17088 claims
Johnson & JohnsonXarelto$247$86,11980 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →